Center-Authored Papers

Filters: Author is Dale, David  [Clear All Filters]
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 
Treatment Outcome
Cosler LE, Sivasubramaniam V, Agboola O, Crawford J, Dale D, Lyman GH.  2005.  Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 8(1):47-52. Abstract
Time Factors
Cosler LE, Eldar-Lissai A, Culakova E, Kuderer NM, Dale D, Crawford J, Lyman GH.  2007.  Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.. PharmacoEconomics. 25(4):343-51. Abstract
Survival Analysis
Cosler LE, Eldar-Lissai A, Culakova E, Kuderer NM, Dale D, Crawford J, Lyman GH.  2007.  Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.. PharmacoEconomics. 25(4):343-51. Abstract
Sensitivity and Specificity
Cosler LE, Sivasubramaniam V, Agboola O, Crawford J, Dale D, Lyman GH.  2005.  Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 8(1):47-52. Abstract
Risk Factors
Cosler LE, Sivasubramaniam V, Agboola O, Crawford J, Dale D, Lyman GH.  2005.  Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 8(1):47-52. Abstract
Risk Assessment
Cosler LE, Sivasubramaniam V, Agboola O, Crawford J, Dale D, Lyman GH.  2005.  Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 8(1):47-52. Abstract
Patient Selection
Cosler LE, Sivasubramaniam V, Agboola O, Crawford J, Dale D, Lyman GH.  2005.  Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 8(1):47-52. Abstract
Patient Discharge
Cosler LE, Eldar-Lissai A, Culakova E, Kuderer NM, Dale D, Crawford J, Lyman GH.  2007.  Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.. PharmacoEconomics. 25(4):343-51. Abstract
New York
Cosler LE, Sivasubramaniam V, Agboola O, Crawford J, Dale D, Lyman GH.  2005.  Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 8(1):47-52. Abstract
NEUTROPENIA
Cosler LE, Sivasubramaniam V, Agboola O, Crawford J, Dale D, Lyman GH.  2005.  Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 8(1):47-52. Abstract
Cosler LE, Eldar-Lissai A, Culakova E, Kuderer NM, Dale D, Crawford J, Lyman GH.  2007.  Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.. PharmacoEconomics. 25(4):343-51. Abstract
Neoplasms
Cosler LE, Sivasubramaniam V, Agboola O, Crawford J, Dale D, Lyman GH.  2005.  Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 8(1):47-52. Abstract
Monte Carlo Method
Cosler LE, Eldar-Lissai A, Culakova E, Kuderer NM, Dale D, Crawford J, Lyman GH.  2007.  Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.. PharmacoEconomics. 25(4):343-51. Abstract
Models, Economic
Cosler LE, Eldar-Lissai A, Culakova E, Kuderer NM, Dale D, Crawford J, Lyman GH.  2007.  Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.. PharmacoEconomics. 25(4):343-51. Abstract
Models, Econometric
Cosler LE, Sivasubramaniam V, Agboola O, Crawford J, Dale D, Lyman GH.  2005.  Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 8(1):47-52. Abstract
Length of Stay
Cosler LE, Eldar-Lissai A, Culakova E, Kuderer NM, Dale D, Crawford J, Lyman GH.  2007.  Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.. PharmacoEconomics. 25(4):343-51. Abstract
Cosler LE, Sivasubramaniam V, Agboola O, Crawford J, Dale D, Lyman GH.  2005.  Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 8(1):47-52. Abstract
Humans
Cosler LE, Sivasubramaniam V, Agboola O, Crawford J, Dale D, Lyman GH.  2005.  Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 8(1):47-52. Abstract
Cosler LE, Eldar-Lissai A, Culakova E, Kuderer NM, Dale D, Crawford J, Lyman GH.  2007.  Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.. PharmacoEconomics. 25(4):343-51. Abstract
Hospitalization
Cosler LE, Eldar-Lissai A, Culakova E, Kuderer NM, Dale D, Crawford J, Lyman GH.  2007.  Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.. PharmacoEconomics. 25(4):343-51. Abstract
Hospital Mortality
Cosler LE, Eldar-Lissai A, Culakova E, Kuderer NM, Dale D, Crawford J, Lyman GH.  2007.  Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.. PharmacoEconomics. 25(4):343-51. Abstract
Hospital Costs
Cosler LE, Sivasubramaniam V, Agboola O, Crawford J, Dale D, Lyman GH.  2005.  Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 8(1):47-52. Abstract
Health Services Research
Cosler LE, Sivasubramaniam V, Agboola O, Crawford J, Dale D, Lyman GH.  2005.  Effect of outpatient treatment of febrile neutropenia on the risk threshold for the use of CSF in patients with cancer treated with chemotherapy.. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 8(1):47-52. Abstract
Granulocyte Colony-Stimulating Factor
Cosler LE, Eldar-Lissai A, Culakova E, Kuderer NM, Dale D, Crawford J, Lyman GH.  2007.  Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.. PharmacoEconomics. 25(4):343-51. Abstract
Fever
Cosler LE, Eldar-Lissai A, Culakova E, Kuderer NM, Dale D, Crawford J, Lyman GH.  2007.  Therapeutic use of granulocyte colony-stimulating factors for established febrile neutropenia: effect on costs from a hospital perspective.. PharmacoEconomics. 25(4):343-51. Abstract